Clinical Lymphoma and Myeloma最新文献_第5页

The 45th Annual Meeting of the American Society of Clinical Oncology Orlando, FL; May 29 – June 2, 2009 第45届美国临床肿瘤学会年会奥兰多，FL;2009年5月29日- 6月2日

Clinical Lymphoma and Myeloma Pub Date : 2009-10-01 DOI: 10.3816/CLM.2009.n.069

Sonia Cunningham PhD, Sabeeha Muneer PhD, Aarati Ranganathan PhD, Bruce Cheson MD, Sundar Jagannath MD

引用次数: 0

IGHV Unmutated Status Influences Outcome More Than IGHV1-69 Gene Usage Per Se in Patients With Chronic Lymphocytic Leukemia IGHV未突变状态对慢性淋巴细胞白血病患者预后的影响大于IGHV1-69基因本身的使用

Clinical Lymphoma and Myeloma Pub Date : 2009-10-01 DOI: 10.3816/CLM.2009.n.076

Ester M. Orlandi, Silvia Zibellini, Cristiana Pascutto, Cristina Picone, Ilaria Giardini, Lara Pochintesta, Mario Lazzarino

引用次数: 4

Management of Immunocompetent Patients With Primary Central Nervous System Lymphoma 免疫功能正常的原发性中枢神经系统淋巴瘤患者的治疗

Clinical Lymphoma and Myeloma Pub Date : 2009-10-01 DOI: 10.3816/CLM.2009.n.070

Emanuela Chimienti, Michele Spina, Emanuela Vaccher, Umberto Tirelli

{"title":"Management of Immunocompetent Patients With Primary Central Nervous System Lymphoma","authors":"Emanuela Chimienti, Michele Spina, Emanuela Vaccher, Umberto Tirelli","doi":"10.3816/CLM.2009.n.070","DOIUrl":"10.3816/CLM.2009.n.070","url":null,"abstract":"<div><p>Primary central nervous system (CNS) lymphoma (PCNSL) is a non-Hodgkin lymphoma that arises within and is confined to the CNS. Recent data have suggested an increasing incidence in immunocompetent individuals, with a peak of incidence between 60 and 70 years of age. Patients with PCNSL present mostly with symptoms of increased intracranial pressure. The clinical management of these patients remains controversial, and the optimal treatment for patients with PCNSL has not yet been defined. Surgery, even if macroscopically radical, does not improve survival because of the multifocal and infiltrative nature of PCNSL; furthermore, the deep location of most of these tumors makes patients susceptible to serious and irreversible neurologic sequelae. Corticosteroids have a specific role in the treatment of patients with PCNSL, whose disease is sensitive to them as a chemotherapeutic agent. PCNSL is an extremely radiation-sensitive neoplasm; whole-brain radiation therapy plus corticosteroids was the first modality of treatment for patients with this neoplasm until 10 years ago, with a low cure rate and a high local recurrence rate. PCNSL is also a chemosensitive neoplasm; while the optimal choice, sequence, and combination of appropriate agents for efficacious treatment of patients with PCNSL has yet to be determined. An essential component of therapy must include an adequate drug delivery behind a normal blood-brain barrier. Methotrexate is the agent with the most proven activity in PCNSL. Combined-modality therapy has improved survival, but relapse is still common, and late neurologic toxicity is a significant complication, especially in older patients, who represent the majority of immunocompetent patients with PCNSL.</p></div>","PeriodicalId":100272,"journal":{"name":"Clinical Lymphoma and Myeloma","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLM.2009.n.070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28461969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Kyphoplasty for Patients With Multiple Myeloma Is a Safe Surgical Procedure: Results From a Large Patient Cohort 多发性骨髓瘤患者的后凸成形术是一种安全的外科手术:来自大型患者队列的结果

Clinical Lymphoma and Myeloma Pub Date : 2009-10-01 DOI: 10.3816/CLM.2009.n.073

Franz-Xaver Huber , Nicholas McArthur , Michael Tanner , Bernd Gritzbach , Oliver Schoierer , Wolfram Rothfischer , Gerhard Krohmer , Erich Lessl , Martin Baier , Peter Jürgen Meeder , Christian Kasperk

{"title":"Kyphoplasty for Patients With Multiple Myeloma Is a Safe Surgical Procedure: Results From a Large Patient Cohort","authors":"Franz-Xaver Huber , Nicholas McArthur , Michael Tanner , Bernd Gritzbach , Oliver Schoierer , Wolfram Rothfischer , Gerhard Krohmer , Erich Lessl , Martin Baier , Peter Jürgen Meeder , Christian Kasperk","doi":"10.3816/CLM.2009.n.073","DOIUrl":"10.3816/CLM.2009.n.073","url":null,"abstract":"<div><h3>Introduction</h3><p>Only in recent years has balloon kyphoplasty gained significance in the treatment of vertebral fractures as an adequate minimally invasive vertebral stabilization technique. Kyphoplasty has also increasingly been used to treat vertebral osteolyses caused by multiple myeloma (MM).</p></div><div><h3>Patients and Methods</h3><p>In our cohort of 76 patients with MM with a total of 190 vertebral fractures treated with kyphoplasty, we performed a 30-day postoperative analysis of cement leakage, neurologic symptoms, pulmonary embolism, and infections.</p></div><div><h3>Results</h3><p>Painful osteolytic or fractured vertebrae or even imminent vertebral instability caused by osteolyses were seen as indications for kyphoplasty. One case of pulmonary embolism was observed because of cement leakage as the only postoperative complication.</p></div><div><h3>Conclusion</h3><p>By careful interdisciplinary indication setting and a standardized treatment model, kyphoplasty presents a very safe and effective procedure for the treatment of vertebral osteolyses and fractures caused by MM.</p></div>","PeriodicalId":100272,"journal":{"name":"Clinical Lymphoma and Myeloma","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLM.2009.n.073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28461972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 38

Rituximab and Dose-Dense Chemotherapy in Primary Testicular Lymphoma 利妥昔单抗和剂量密集化疗治疗原发性睾丸淋巴瘤

Clinical Lymphoma and Myeloma Pub Date : 2009-10-01 DOI: 10.3816/CLM.2009.n.075

Agustin Avilés , M. Jesús Nambo , Sergio Cleto , Natividad Neri , Judith Huerta-Guzmán

{"title":"Rituximab and Dose-Dense Chemotherapy in Primary Testicular Lymphoma","authors":"Agustin Avilés , M. Jesús Nambo , Sergio Cleto , Natividad Neri , Judith Huerta-Guzmán","doi":"10.3816/CLM.2009.n.075","DOIUrl":"10.3816/CLM.2009.n.075","url":null,"abstract":"<div><h3>Background</h3><p>Treatment of primary testicular lymphoma (PTL) remains unsatisfactory even in patients with good prognosis, as < 30% of patients are alive at 3 years.</p></div><div><h3>Patients and Methods</h3><p>We began a phase II study to assess efficacy and toxicity of a dose-dense cyclophosphamide/epirubicin/vincristine/prednisone (CEOP14) regimen with rituximab (CEOP14R) in 38 previously untreated patients with PTL with early-stage (I or II) and low-risk disease, followed by adjuvant radiation therapy and central nervous system prophylaxis.</p></div><div><h3>Results</h3><p>Complete response was 86% (similar to historical controls), but improvement in outcome was observed; with actuarial curves at 5 years, event-free survival was 70%, and overall survival was 66%. Toxicity was mild, and the regimen was well tolerated.</p></div><div><h3>Conclusion</h3><p>The addition of rituximab to dose-dense chemotherapy improves outcome in this setting of patients who previously had been considered to have the poorest prognosis. It is important that these findings will be validated in multicentric, controlled clinical trials.</p></div>","PeriodicalId":100272,"journal":{"name":"Clinical Lymphoma and Myeloma","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLM.2009.n.075","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28459613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 25

Low-Dose Gemcitabine Efficacious in Three Patients With Tumor-Stage Mycosis Fungoides 低剂量吉西他滨对3例肿瘤期蕈样真菌病有效

Clinical Lymphoma and Myeloma Pub Date : 2009-10-01 DOI: 10.3816/CLM.2009.n.079

Timo Buhl, Hans P. Bertsch, Kjell M. Kaune, Christina Mitteldorf, Michael P. Schön, Lutz Kretschmer

引用次数: 7

Clinical Lymphoma & Myeloma … and Leukemia Too! 临床淋巴瘤、骨髓瘤和白血病!

Clinical Lymphoma and Myeloma Pub Date : 2009-10-01 DOI: 10.3816/CLM.2009.n.068

Jorge E. Cortés MD

引用次数: 4

Multiple Bony Amyloidomas as an Initial Presentation of Myeloma 多发性骨性淀粉样瘤是骨髓瘤的最初表现

Clinical Lymphoma and Myeloma Pub Date : 2009-10-01 DOI: 10.3816/CLM.2009.n.078

Dean M. Kirkel , Edina Paal , Joao Ascensao , Geraldine P. Schechter

引用次数: 1

Minimal Residual Disease Quantitation in Acute Myeloid Leukemia 急性髓系白血病微量残留病定量分析

Clinical Lymphoma and Myeloma Pub Date : 2009-09-01 DOI: 10.3816/CLM.2009.s.024

David Shook , Elaine Coustan-Smith , Raul C. Ribeiro , Jeffrey E. Rubnitz , Dario Campana

{"title":"Minimal Residual Disease Quantitation in Acute Myeloid Leukemia","authors":"David Shook , Elaine Coustan-Smith , Raul C. Ribeiro , Jeffrey E. Rubnitz , Dario Campana","doi":"10.3816/CLM.2009.s.024","DOIUrl":"10.3816/CLM.2009.s.024","url":null,"abstract":"<div><p>The prognosis for patients with acute myeloid leukemia (AML) is heterogeneous. A minority of patients have clinical and biologic features associated with a very high risk of relapse. For the remaining patients, no clear prognostic factors can be identified at diagnosis. The degree of treatment response is likely to be an informative predictor of outcome for these patients. Modern assays to detect AML cells that are undetectable by conventional morphologic techniques, ie, minimal residual disease (MRD), can potentially improve measurements of treatment response. It is plausible that modifications to treatment based on the results of these assays will improve clinical management and ultimately increase cure rates. Established MRD assays for AML are based on either polymerase chain reaction amplification of genetic abnormalities or flow cytometric detection of abnormal immunophenotypes. Residual disease and treatment response can be measured by these assays in a manner that is much more sensitive and objective than that afforded by conventional morphologic examination. The expanding use of MRD testing is beginning to change the definitions of treatment response and of remission. Other clinically informative uses of MRD testing include the detection of early relapse and the evaluation of the efficacy of new antileukemic agents.</p></div>","PeriodicalId":100272,"journal":{"name":"Clinical Lymphoma and Myeloma","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLM.2009.s.024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40033574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 47

Hairy Cell Leukemia 毛细胞白血病

Clinical Lymphoma and Myeloma Pub Date : 2009-09-01 DOI: 10.3816/CLM.2009.s.020

Farhad Ravandi

引用次数: 1